Jaclyn Essig (Ph.D.) is a Principal Scientist at Regel Therapeutics, where she leads a team developing gene therapies for rare diseases caused by haploinsufficiency. Her work focuses on using a modified CRISPR-Cas system to upregulate gene expression and restore healthy function. By optimizing guide RNAs and engineering activator proteins, Jacki is helping push this innovative, translational science closer to clinical impact.